JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Hospital of the University of Pennsylvania
Filadelfia, Estados UnidosPublicaciones en colaboración con investigadores/as de Hospital of the University of Pennsylvania (12)
2023
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood, Vol. 141, Núm. 3, pp. 219-230
2022
-
Teclistamab in Relapsed or Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505
2021
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
2011
-
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 38-43
2009
-
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
Leukemia, Vol. 23, Núm. 10, pp. 1904-1912
-
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
European Journal of Haematology, Vol. 82, Núm. 6, pp. 426-432
-
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903
2008
-
Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study
Leukemia, Vol. 22, Núm. 4, pp. 842-849
2007
-
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435
2005
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498